Biotech Startups

Cytomos develops AuraCyt®, a microelectronics-based biotechnology platform for real-time single-cell analytics in bioprocessing and cell and gene therapy manufacturing. The company serves large biotech and pharma companies seeking cost-effective process analytical technology solutions for drug development and manufacturing.

1 investor

Cyto Recovery develops technology for label-free cell sorting and gentle sample cleanup for cell populations, aimed at life-science and research users. Its products are positioned as tools for separating and purifying cells without labeling.

1 investor

Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.

1 investor

Cytovation develops immunotherapy treatments designed to enhance immune response against various cancer types, with a focus on engineered synthetic peptides and first-in-class therapeutic candidates. The company is built on research foundations from Norwegian academic institutions and serves oncology and immunology markets.

1 investor

Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.

1 investor

Cytura Therapeutics is a pharmaceutical company focused on drug discovery and development, with backing from academic research institutions and venture capital firms specializing in biotech and medtech investments.

1 investor

1 investor

DP Bio Innovations is developing an implantable, bioresorbable medical device that regenerates a damaged esophagus inside the body, intended to treat patients with severe GERD/advanced Barrett's Esophagus, esophageal cancer, and pediatric esophageal defects. The device aims to avoid surgical reconstruction such as gastric pull-up and reduce treatment costs compared to the standard of care.

1 investor

D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.

1 investor

Data2Discovery builds a knowledge graph and data science software platform that integrates and analyzes large, complex, heterogeneous datasets to surface insights in fields such as drug discovery, disaster medicine, and food science. It serves pharmaceutical, biotech, research, and government organizations, with applications including drug repurposing, toxicology, and phenotypic analysis.

1 investor

1 investor

Da Capo develops therapies aimed at halting the progression of neurodegenerative disease, using a target and drug discovery platform that combines data analytics, network biology, human iPS cell models, and chemistry and phenotypic screening. It focuses on recapitulating human neurodegenerative biology to identify disease drivers and move from target to lead compound.

1 investor

Dahlia develops RNA Flow Assays that let researchers detect specific RNA targets at the single-cell level using standard fluorescence-based flow cytometers, enabling measurement of non-coding RNA and proteins that lack quality antibodies. It sells target-specific RNA Flow Probe Sets and universal RNA Flow Assay Reagent Kits for life sciences research applications such as validating single-cell RNA sequencing and enriching rare cell populations.

1 investor

1 investor

DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.

1 investor

Dalriada is a contract research organization providing integrated small molecule drug discovery services for global biotech and pharmaceutical companies. The company operates an interdisciplinary team under one roof offering full-suite drug discovery expertise from target identification through pre-clinical development.

1 investor

Dalton Bioanalytics develops comprehensive biochemical analysis of humans in a single test, aimed at advancing preventative healthcare.

1 investor

DaltonTx builds an AI-enabled cloud platform for drug discovery, covering the full lifecycle from data ingestion and model training to molecule generation and experiment prioritisation for both biologics and small molecules. It serves pharma, biotech, and CROs, positioning itself as R&D infrastructure that combines human scientific expertise with machine intelligence.

1 investor

Danaher is a global science and technology company specializing in biotech, diagnostics, and life sciences with businesses that innovate in drug development, molecular diagnostics, genomic medicine, and bioprocessing to help advance human health. Operating through multiple strategic platforms and with nearly 63,000 employees, Danaher develops technologies and solutions for researchers, biopharmaceutical producers, and healthcare systems globally.

1 investor

Dark Blue Therapeutics develops novel medicines for cancer through integrated drug discovery combining internal expertise with academic partnerships. The company focuses on identifying transformative therapeutic approaches across multiple cancer mechanisms.

1 investor

Darwin Bioprospecting converts microbial diversity into industrial solutions, leveraging microbial strains and genomics for applications across health, nutrition, and biosolutions.

1 investor

DataHow develops AI-powered design of experiments software for bioprocess development, using hybrid modeling to combine mechanistic knowledge with machine learning to reduce experimental cycles and accelerate process understanding.

1 investor

Datar Cancer Genetics is a healthcare company focused on cancer diagnostics and genetics. The company provides statutory investor relations information and annual reports for shareholders.

1 investor

dawn-bio develops a human stem-cell based embryo and implantation model to study early human embryo development and implantation. Its technology is aimed at IVF clinics to help create more and healthier embryos and improve success rates in reproductive medicine.

1 investor